Dr Mark Bloch

de Looze F; Russo M; Bloch M; Montgomery B; Shephard A; DeVito R, 2018, 'Meaningful relief with flurbiprofen 8.75 mg spray in patients with sore throat due to upper respiratory tract infection', Pain management, vol. 8, pp. 79 - 83, http://dx.doi.org/10.2217/pmt-2017-0100

Bavinton BR; Pinto AN; Phanuphak N; Grinsztejn B; Prestage GP; Zablotska-Manos IB; Jin F; Fairley CK; Moore R; Roth N, 2018, 'Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study', The Lancet HIV, vol. 5, pp. e438 - e447, http://dx.doi.org/10.1016/S2352-3018(18)30132-2

Philpot SP; Prestage G; Ellard J; Grulich AE; Bavinton BR, 2018, 'How do gay serodiscordant couples in Sydney, Australia negotiate undetectable viral load for HIV prevention?', AIDS and Behavior, vol. 22, pp. 3981 - 3990, http://dx.doi.org/10.1007/s10461-018-2247-6

Unal G; Alessandri-Gradt E; Leoz M; Pavie J; Lefèvre C; Panjo H; Charpentier C; Descamps D; Barin F; Simon F, 2018, 'Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals', Clinical Infectious Diseases, vol. 66, pp. 1785 - 1793, http://dx.doi.org/10.1093/cid/cix1087

Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L, 2018, 'Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial', The Lancet HIV, vol. 5, pp. e211 - e220, http://dx.doi.org/10.1016/S2352-3018(18)30021-3

Bruneel F; Tubach F; Mira JP; Houze S; Gibot S; Huisse MG; Megarbane B; Choquet C; Corne P; Peytel E, 2018, 'Correction to: Imported falciparum malaria in adults: host- and parasite-related factors associated with severity. The French prospective multicenter PALUREA cohort study (Intensive Care Medicine, (20', Intensive Care Medicine, vol. 44, pp. 141 - 143, http://dx.doi.org/10.1007/s00134-017-4978-7

Stirrup OT; Copas AJ; Phillips AN; Gill MJ; Geskus RB; Touloumi G; Young J; Bucher HC; Babiker AG; Kelleher T, 2018, 'Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion', HIV Medicine, vol. 19, pp. 184 - 194, http://dx.doi.org/10.1111/hiv.12567

Ferrer PE; Bloch M; Roth N; Finlayson R; Baker D; Koh K; Orth D; Urbaityte R; Brown D; Drummond F, 2018, 'A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes', International Journal of STD and AIDS, vol. 29, pp. 300 - 305, http://dx.doi.org/10.1177/0956462417730474

Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J, 2018, 'Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): Design of an open label, single arm implementation trial', BMC Public Health, vol. 18, http://dx.doi.org/10.1186/s12889-017-5018-9

Soodla P; Simmons R; Huik K; Pauskar M; Jõgeda EL; Rajasaar H; Kallaste E; Maimets M; Avi R; Murphy G, 2018, 'HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay', HIV Medicine, vol. 19, pp. 33 - 41, http://dx.doi.org/10.1111/hiv.12535

Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK, 2018, 'Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy', AIDS, vol. 32, pp. 35 - 48, http://dx.doi.org/10.1097/QAD.0000000000001685

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, vol. 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532

Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M, 2017, 'Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parall', The Lancet HIV, vol. 4, pp. e486 - e494, http://dx.doi.org/10.1016/S2352-3018(17)30128-5

Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G, 2017, 'Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial', The Lancet Infectious Diseases, vol. 17, pp. 1255 - 1265, http://dx.doi.org/10.1016/S1473-3099(17)30476-0

Smoleń-Dzirba J; Rosińska M; Janiec J; Beniowski M; Cycoń M; Bratosiewicz-Wąsik J; Wasik TJ; Kelleher T; Cooper D; Grey P, 2017, 'HIV-1 infection in persons homozygous for CCR5-Δ32 allele: The next case and the review', AIDS Reviews, vol. 19, pp. 219 - 230

Petoumenos K; Huang R; Hoy J; Bloch M; Templeton DJ; Baker D; Giles M; Law MG; Cooper DA, 2017, 'Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years - The Australian Positive & Peers Longevity Evaluation Study (APPLES)', PLoS ONE, vol. 12, http://dx.doi.org/10.1371/journal.pone.0184583

Pozniak A; Flamm J; Antinori A; Bloch M; Ward D; Berenguer J; Cote P; Andreatta K; Garner W; Szwarcberg J, 2017, 'Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF', HIV Clinical Trials, vol. 18, pp. 141 - 148, http://dx.doi.org/10.1080/15284336.2017.1338844

Hey-Nguyen WJ; Xu Y; Pearson CF; Bailey M; Suzuki K; Tantau R; Obeid S; Milner B; Field A; Carr A, 2017, 'Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes during Antiretroviral Therapy', AIDS Research and Human Retroviruses, vol. 33, pp. 648 - 657, http://dx.doi.org/10.1089/aid.2016.0171

Kamminga J; Lal L; Wright EJ; Bloch M; Brew BJ; Cysique LA, 2017, 'Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use', Current HIV/AIDS Reports, vol. 14, pp. 83 - 92, http://dx.doi.org/10.1007/s11904-017-0349-9

Puhr R; Petoumenos K; Youds D; Law MG; Templeton DJ; Ellis D; Bloch M; Agrawal S; Vincent T; Allen D, 2017, 'The impact of changes in HIV management guidelines on time to treatment initiation in Australia', HIV Medicine, vol. 18, pp. 701 - 703, http://dx.doi.org/10.1111/hiv.12504

Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA, 2017, 'Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure', Journal of Clinical and Experimental Neuropsychology, vol. 39, pp. 753 - 767, http://dx.doi.org/10.1080/13803395.2016.1263282

Lortholary O; Roussillon C; Boucherie C; Padoin C; Chaix ML; Breton G; Rami A; Veziris N; Patey O; Caumes E, 2016, 'Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: The ANRS 129 BKVIR trial', Journal of Antimicrobial Chemotherapy, vol. 71, pp. 783 - 793, http://dx.doi.org/10.1093/jac/dkv384

Pozniak A; Arribas JR; Gathe J; Gupta SK; Post FA; Bloch M; Avihingsanon A; Crofoot G; Benson P; Lichtenstein K, 2016, 'Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-', Journal of Acquired Immune Deficiency Syndromes, vol. 71, pp. 530 - 537, http://dx.doi.org/10.1097/QAI.0000000000000908

Bloch M; Kamminga J; Jayewardene A; Bailey M; Carberry A; Vincent T; Quan D; Maruff P; Brew B; Cysique LA, 2016, 'A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review', Clinical Infectious Diseases, vol. 63, pp. 687 - 693, http://dx.doi.org/10.1093/cid/ciw399

Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2016, 'Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection', Open Forum Infectious Diseases, vol. 3, http://dx.doi.org/10.1093/ofid/ofw105

Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I, 2016, 'Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE', BMJ Open, vol. 6, http://dx.doi.org/10.1136/bmjopen-2016-012179

Lee FJ; Marriott D; Bloch M; Richardson R; Mackenzie N; Carr A, 2016, 'Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART', Journal of Antimicrobial Chemotherapy, vol. 71, pp. 1127 - 1129, http://dx.doi.org/10.1093/jac/dkv436

de Looze F; Russo M; Bloch M; Montgomery B; Shephard A; Smith G; Aspley S, 2016, 'Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial', European Journal of General Practice, vol. 22, pp. 111 - 118, http://dx.doi.org/10.3109/13814788.2016.1145650

Lee F; Monteiro P; Baker D; Bloch M; Roth N; Finlayson R; Moore R; Hoy J; Martinez E; Carr A, 2016, 'Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: A randomized trial', HIV Medicine, http://dx.doi.org/10.1111/hiv.12362

Van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W, 2016, 'Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study', AIDS, vol. 30, pp. 251 - 259, http://dx.doi.org/10.1097/QAD.0000000000000911

Seng R; Goujard C; Krastinova E; Miailhes P; Orr S; Molina JM; Saada M; Piroth L; Rouzioux C; Meyer L, 2015, 'Influence of lifelong cumulative HIV viremia on long-term recovery of CD4⁺ cell count and CD4⁺/CD8⁺ ratio among patients on combination antiretroviral therapy', AIDS, vol. 29, pp. 595 - 607, http://dx.doi.org/10.1097/QAD.0000000000000571

Lang S; Lacombe JM; Mary-Krause M; Partisani M; Bidegain F; Cotte L; Aslangul E; Chéret A; Boccara F; Meynard JL, 2015, 'Is impact of statin therapy on all-cause mortality different in HIV-infected individuals compared to general population? Results from the FHDH-ANRS CO4 cohort', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0133358

Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C, 2015, 'Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial', The Lancet HIV, vol. 2, pp. e319 - e327, http://dx.doi.org/10.1016/S2352-3018(15)00114-9

Hoehn KB; Gall A; Bashford-Rogers R; Fidler SJ; Kaye S; Weber JN; McClure MO; Kellam P; Pybus OG, 2015, 'Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals', Philosophical transactions of the Royal Society of London. Series B, Biological sciences, vol. 370, http://dx.doi.org/10.1098/rstb.2014.0241

Abgrall S; Rachas A; Tourret J; Isnard-Bagnis C; Billaud E; Tattevin P; Costagliola D; Guiguet M; Durieux P; Abgrall S, 2015, 'A Multifaceted Intervention Designed to Improve Medical Management of Moderate to Advanced Chronic Kidney Disease in HIV-Infected Patients: A Cluster Randomized Trial', Clinical Infectious Diseases, vol. 61, pp. 375 - 384, http://dx.doi.org/10.1093/cid/civ310

Jarrin I; Pantazis N; Dalmau J; Phillips AN; Olson A; Mussini C; Boufassa F; Costagliola D; Porter K; Blanco J, 2015, 'Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?', AIDS, vol. 29, pp. 2323 - 2333, http://dx.doi.org/10.1097/QAD.0000000000000805

Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S, 2015, 'Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0139981

Templeton DJ; Wright ST; McManus H; Lawrence C; Russell DB; Law MG; Petoumenos K; Ellis D; Bloch M; Agrawal S, 2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, vol. 15, http://dx.doi.org/10.1186/s12879-015-1051-4

Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2015.05.003

Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhaus J; Fux CA, 2015, 'Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study', PLoS Medicine, vol. 12, http://dx.doi.org/10.1371/journal.pmed.1001809

Wright ST; Law MG; Cooper DA; Keen P; McDonald A; Middleton M; Woolley I; Kelly M; Petoumenos K; Ellis D, 2015, 'Temporal trends of time to antiretroviral treatment initiation, interruption and modification: Examination of patients diagnosed with advanced HIV in Australia', Journal of the International AIDS Society, vol. 18, http://dx.doi.org/10.7448/IAS.18.1.19463

Han N; Wright ST; O'Connor CC; Hoy J; Ponnampalavanar S; Grotowski M; Zhao HX; Kamarulzaman A; Ellis D; Bloch M, 2015, 'HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD)', HIV Medicine, vol. 16, pp. 152 - 160, http://dx.doi.org/10.1111/hiv.12188

Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L, 2014, 'Dolutegravir: Clinical and laboratory safety in integrase inhibitor-naive patients', HIV Clinical Trials, vol. 15, pp. 199 - 208, http://dx.doi.org/10.1310/hct1505-199

Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D, 2014, 'Week 48 results from a randomized clinical trial of rilpivirine/ emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/ tenofovir disoproxil fumarate in treatment-naive HIV-1-infecte', AIDS, vol. 28, pp. 989 - 997, http://dx.doi.org/10.1097/QAD.0000000000000169

Bieber T; Chosidow O; Bodsworth N; Tyring S; Hercogova J; Bloch M; Davis M; Lewis M; Boutolleau D; Attali P, 2014, 'Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP trial): A double-blind, placebo-controlled, self-initiated trial', Journal of Drugs in Dermatology, vol. 13, pp. 791 - 798

Bloch M; Tong W; Lee F; Richardson R; Carr A; Hoy J; Baker D, 2014, 'Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks', HIV Medicine, http://dx.doi.org/10.1111/hiv.12123

Cordel H; Cailhol J; Matheron S; Bloch M; Godineau N; Consigny PH; Gros H; Campa P; Bourée P; Fain O, 2013, 'Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: A prospective observational study of 553 cases', Malaria Journal, vol. 12, http://dx.doi.org/10.1186/1475-2875-12-399

Russo M; Bloch M; Looze FD; Morris C; Shephard A, 2013, 'Flurbiprofen microgranules for relief of sore throat: A randomised, double-blind trial', British Journal of General Practice, vol. 63, http://dx.doi.org/10.3399/bjgp13X663118

Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F, 2013, 'Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study', The Lancet, vol. 381, pp. 735 - 743, http://dx.doi.org/10.1016/S0140-6736(12)61853-4

Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S, 2013, 'Rilpivirine versus efavirenz in hiv-1-infected subjects receiving emtricitabine/tenofovir df: Pooled 96-week data from ECHO and THRIVE studies', HIV Clinical Trials, vol. 14, pp. 81 - 91, http://dx.doi.org/10.1310/hct1403-81

Worm SW; Bower M; Reiss P; Bonnet F; Law M; Fätkenheuer G; d'Arminio Monforte A; Abrams DI; Grulich A; Fontas E, 2013, 'Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study', BMC Infectious Diseases, vol. 13, http://dx.doi.org/10.1186/1471-2334-13-471

Lee FJ; Amin J; Bloch M; Pett SL; Marriott D; Carr A, 2013, 'Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults', Journal of Acquired Immune Deficiency Syndromes, vol. 62, pp. 525 - 533, http://dx.doi.org/10.1097/QAI.0b013e3182832578

Nelson M; Amaya G; Clumeck N; Arns da cunha C; Jayaweera D; Junod P; Li T; Tebas P; Stevens M; Buelens A, 2012, 'Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE t', Journal of Antimicrobial Chemotherapy, vol. 67, pp. 2020 - 2028, http://dx.doi.org/10.1093/jac/dks130

Twiss J; McKenna SP; Bloch M; Bonney M, 2012, 'Erratum: Patient and clinician perceived benefit of early consumption of famciclovir for the treatment of herpes outbreaks. Value in Health (2011) 14:7 (A266))', Value in Health, vol. 15, pp. 789, http://dx.doi.org/10.1016/j.jval.2012.07.001

Schlesinger N; Alten RE; Bardin T; Schumacher HR; Bloch M; Gimona A; Krammer G; Murphy V; Richard D; So AK, 2012, 'Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions', Annals of the Rheumatic Diseases, vol. 71, pp. 1839 - 1848, http://dx.doi.org/10.1136/annrheumdis-2011-200908

Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; Allworth A; Anderson J; Baker D; Bloch M, 2012, 'Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0038377

Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M, 2012, 'Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology (Australia), vol. 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Bloch M; Farris M; Tilden D; Gowers A; Cunningham N, 2010, 'Triple-class HIV antiretroviral therapy failure in an Australian primary care setting', Sexual Health, vol. 7, pp. 17 - 24, http://dx.doi.org/10.1071/SH09039

Grebely J; Petoumenos K; Hellard M; Matthews GV; Suppiah V; Applegate T; Yeung B; Marks P; Rawlinson W; Lloyd AR, 2010, 'Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection', Hepatology, vol. 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A, 2010, 'No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial', HIV Medicine, vol. 11, pp. 493 - 501, http://dx.doi.org/10.1111/j.1468-1293.2009.00817.x

Amin J; Martin A; Bloch M; Carr A, 2010, 'Reply to Landman and Soonawala', Clinical Infectious Diseases, vol. 50, pp. 1200 - 1201, http://dx.doi.org/10.1086/651469

Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP, 2009, 'Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: The 2IP ANRS 127 study', Journal of Antimicrobial Chemotherapy, vol. 64, pp. 118 - 125, http://dx.doi.org/10.1093/jac/dkp146

Meads DM; McKenna SP; Bonney MA; Bloch MT, 2009, 'Further validation and responsiveness assessment of the herpes outbreak impact questionnaire and herpes symptom checklist', Value in Health, vol. 12, pp. 397 - 400, http://dx.doi.org/10.1111/j.1524-4733.2008.00450.x

Mitsuyasu RT; Merigan TC; Carr A; Zack JA; Winters MA; Workman C; Bloch M; Lalezari J; Becker S; Thornton L, 2009, 'Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 ⁺ cells', Nature Medicine, vol. 15, pp. 285 - 292, http://dx.doi.org/10.1038/nm.1932

Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A, 2009, 'Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial', Clinical Infectious Diseases, vol. 49, pp. 1591 - 1601, http://dx.doi.org/10.1086/644769

D'Arminio Monforte A; Abrams D; Pradier C; Weber R; Reiss P; Bonnet F; Kirk O; Law M; De Wit S; Friis-Møller N, 2008, 'HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies', AIDS, vol. 22, pp. 2143 - 2153, http://dx.doi.org/10.1097/QAD.0b013e3283112b77

Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study', Sexual Health, vol. 5, pp. 219 - 225, http://dx.doi.org/10.1071/SH08013

Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study (Sexual Health (2008) 5, 3, (219-225))', Sexual Health, vol. 5, pp. 379, http://dx.doi.org/10.1071/SH08013_CO

Lowy M; Collins S; Bloch M; Gillman M; Lording D; Sutherland P; Wang H; Stecher V, 2007, 'Quality of erection questionnaire correlates: Change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction', Journal of Sexual Medicine, vol. 4, pp. 83 - 92, http://dx.doi.org/10.1111/j.1743-6109.2006.00398.x

Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD, 2007, 'Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled st', Journal of Acquired Immune Deficiency Syndromes, vol. 46, pp. 125 - 133, http://dx.doi.org/10.1097/QAI.0b013e318157131c

Emery S; Kelleher AD; Workman C; Puls RL; Bloch M; Baker D; Anderson J; Hoy J; Ip S; Nalliah K, 2007, 'Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, vol. 3, pp. 260 - 267, http://dx.doi.org/10.4161/hv.4627

Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; Phillips A; Ruxrungtham K, 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, vol. 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x

Collins S; Mertenskoetter T; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD, 2006, 'Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D Study', Archives of Internal Medicine, vol. 166, pp. 1632 - 1641, http://dx.doi.org/10.1001/archinte.166.15.1632

Gold J; Batterham MJ; Rekers H; Harms MK; Geurts TBP; Helmyr PME; Silva de Mendonça J; Carvalho LHF; Panos G; Pinchera A, 2006, 'Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting', HIV Medicine, vol. 7, pp. 146 - 155, http://dx.doi.org/10.1111/j.1468-1293.2006.00358.x

Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders JJ; Petoumenos K; Irvine K; Law M; Grey P; Finlayson RJ, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (pulse)', Journal of Acquired Immune Deficiency Syndromes, vol. 42, pp. 192 - 202, http://dx.doi.org/10.1097/01.qai.0000219779.50668.e6

Pett SL; Wand H; Law MG; Arduino R; Lopez JC; Knysz B; Pereira LC; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, vol. 7, pp. 70 - 85, http://dx.doi.org/10.1310/4733-ACQF-F3P4-2QAC

Chee CC; Mortier E; Dupont C; Bloch M; Simonpoli AM; Rouveix E, 2005, 'Medical and social differences between French and migrant patients consulting for the first time for HIV infection', AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, vol. 17, pp. 516 - 520, http://dx.doi.org/10.1080/09540120412331291760

Ray JE; Marriott D; Bloch MT; McLachlan AJ, 2005, 'Therapeutic drug monitoring of atazanavir: Surveillance of pharmacotherapy in the clinic', British Journal of Clinical Pharmacology, vol. 60, pp. 291 - 299, http://dx.doi.org/10.1111/j.1365-2125.2005.02413.x

Kinloch-De Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A, 2005, 'Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection', Journal of Infectious Diseases, vol. 192, pp. 607 - 617, http://dx.doi.org/10.1086/432002

Winston A; Bloch M; Carr A; Amin J; Mallon PWG; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, vol. 56, pp. 380 - 387, http://dx.doi.org/10.1093/jac/dki235

Van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJP, 2004, 'Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1', PLoS Medicine, vol. 1, pp. 064 - 074, http://dx.doi.org/10.1371/journal.pmed.0010019

Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA; Macrae K, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, vol. 5, pp. 192 - 200, http://dx.doi.org/10.1310/0GU7-6X27-MMHE-5ALE

Levy Y; Durier C; Krzysiek R; Rabian C; Capitant C; Lascaux AS; Michon C; Oksenhendler E; Weiss L; Gastaut JA, 2003, 'Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial', AIDS, vol. 17, pp. 343 - 351, http://dx.doi.org/10.1097/00002030-200302140-00008

Mortier E; Toure S; Seyler C; Bloch M; Anglaret X, 2003, 'Urinary pH in HIV-infected adults in Ivory Coast and in France [3]', AIDS, vol. 17, pp. 2003 - 2005, http://dx.doi.org/10.1097/00002030-200309050-00028

Kaufmann GR; Bloch M; Finlayson R; Zaunders J; Smith D; Cooper DA, 2002, 'The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy', AIDS, vol. 16, pp. 359 - 367, http://dx.doi.org/10.1097/00002030-200202150-00007

Bloch M, 2001, 'Current tren HIV therapy', Current Therapeutics, vol. 42, pp. 8 - 12

Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM, 1997, 'Increased frequency of CCR-5 Δ32 heterozygotes among long-term non-progressors with HIV-1 infection', AIDS, vol. 11, pp. 1833 - 1838, http://dx.doi.org/10.1097/00002030-199715000-00007

Bloch MW; Smith DA; Nelson DL, 1989, 'Heart rate, activity, duration, and affect in added-purpose versus single-purpose jumping activities.', The American journal of occupational therapy. : official publication of the American Occupational Therapy Association, vol. 43, pp. 25 - 30, http://dx.doi.org/10.5014/ajot.43.1.25